急性缺血性脑卒中患者血清PAI-1、Aβ水平及其与病情严重程度的相关性分析

秦雪; 赵伟金; 董春瑶

doi:10.13201/j.issn.1009-5918.2017.04.008

急性缺血性脑卒中患者血清PAI-1、Aβ水平及其与病情严重程度的相关性分析

- 沈阳市第一人民医院神经内五科(沈阳, 110041)

详细信息

通讯作者: 秦雪, E-mail:qxue@foxmail.com

中图分类号: R743.3

收稿日期: 2017-02-08

The levels of serum PAI-1,Aβin patients with acute ischemic stroke and correlation analysis with severity

- Department of Neurology, Shenyang First People's Hospital, Shenyang 110041, China

More Information

Corresponding author: QIN Xue, E-mail: qxue@foxmail.com

Received Date: 08 February 2017

摘要

摘要: 目的: 探讨急性缺血性脑卒中(AIS)患者血清1型纤溶酶原激活物抑制剂(PAI-1)、β淀粉样蛋白(Aβ)水平及其与病情严重程度的相关性。方法: 收集2015-03-2016-11我院收治的69例AIS患者(观察组)病例资料,于入院24 h内进行美国国立卫生院卒中量表(NIHSS)评分,并进行神经功能缺损程度评分。根据NIHSS评分及神经功能缺损程度评分,将69例观察组患者分为轻型(16例)、中型(44例)、重型(9例)3个亚组,同时收集23例健康体检者为对照组。用ELISA法检测2组血清PAI-1、Aβ水平。观察组血清PAI-1、Aβ水平与神经功能缺损程度评分的Pearson相关分析。结果: 观察组血清PAI-1、Aβ水平[(49.34±10.72) mg/L、(176.38±92.46) pg/ml]与对照组[(36.87±8.56) mg/L、(142.25±81.43) pg/ml]比较,差异有统计学意义(P<0.05)。中型组血清PAI-1、Aβ水平[(51.25±9.68) mg/L、(178.47±96.32) pg/ml)]、重型组血清PAI-1、Aβ水平[(55.47±13.43) mg/L、(216.32±117.45) pg/ml]分别与轻型组[(42.54±7.62) mg/L、(152.35±82.56) g/ml]比较,差异均有统计学意义(P<0.05)。重型组血清Aβ水平与中型组比较差异有统计学意义[(216.32±117.45) pg/ml vs.(178.47±96.32) pg/ml,P<0.05]。重型组血清PAI-1水平高于中型组,但差异无统计学意义[(55.47±13.43) mg/L vs.(51.25±9.68) mg/L,P>0.05]。Pearson相关分析显示,血清PAI-1水平与AIS病情严重程度(神经功能缺损程度评分)之间呈正相关(r=0.941,P<0.01)。血清Aβ水平与AIS病情严重程度(神经功能缺损程度评分)之间呈正相关(r=0.882,P<0.01)。结论: AIS患者存在血清PAI-1、Aβ水平升高。Pearson相关分析显示:血清PAI-1、Aβ水平与AIS患者病情严重程度呈正相关,提示血清PAI-1、Aβ水平是AIS病情严重程度的重要指标,可为临床评价AIS病情严重程度提供重要的参考价值。
- 急性缺血性脑卒中 /
- 1型纤溶酶原激活物抑制剂 /
- β淀粉样蛋白 /
- 病情严重程度 /
- 相关性分析
Abstract: Objective: To explore serum levels of plasminogen activator inhibitor-1 (PAI-1)and amyloid β (Aβ) in patients with acute ischemic stroke (AIS) and analysis correlation with severity. Method: A total of 69 AIS patients were enrolled in this study as observation group.The National Institutes of Health Stroke Scale (NIHSS) score and the neurological deficit score was performed with in 24 hours of admission.Sixty nine patients were divided into mild (n=16),moderate (n=44) and severe (n=9) according to their NIHSS score and neurological deficit score.Twenty three healthy subjects were enrolled as the control group.Serum levels of PAI-1 and Aβ were detected by ELISA.Pearson correlation analysis of serum levels of PAI-1,Aβ and neurological deficit score was performed in the observation group. Result: Serum levels of PAI-1 and Aβ in the observation group[(49.34±10.72) mg/L、(176.38±92.46) pg/ml] were higher than those in the control group[(36.87±8.56) mg/L、(142.25±81.43) pg/ml](P<0.05).The levels of serum PAI-1 and Aβ in the moderate group[(51.25±9.68) mg/L、(178.47±96.32) pg/ml)],and in the severe group[(55.47±13.43) mg/L、(216.32±117.45) pg/ml)] were higher than those in the mild group[(42.54±7.62) mg/L、(152.35±82.56) g/ml](P<0.05),respectively.The level of serum Aβ in the severe group were significantly different from that in the moderate group[(216.32±117.45) pg/ml vs.(178.47±96.32) pg/ml,P<0.05].The level of serum PAI-1 in the severe group were higher than those in the moderate group,but the difference was not statistically significant[(55.47±13.43) mg/L vs.(51.25±9.68) mg/L,P>0.05].Pearson correlation analysis manifested the level of serumPAI-1 and Aβ were positively correlated with the severity of AIS (the neurological deficit score) respectively (r=0.941,P<0.01;r=0.882,P<0.01). Conclusion: Serum levels of PAI-1 and Aβ were elevated in AIS patients.Pearson corre-lation analysis demonstrated that the levels of serum PAI-1 and Aβ were both positively correlated with the severity of AIS (the neurological deficit score),which suggested that the levels of serum PAI-1 and Aβ may be important indicators of the severity of AIS and could provide crucial reference for clinical evaluation of the severity of AIS.
- acute ischemic stroke /
- plasminogen activator inhibitor-1 /
- amyloidβ /
- severity /
- pearson correlation analysis

HTML全文

参考文献(14)

[1]	Siket M S.Treatment of acute ischemic stroke[J].Emerg Med Clin North Am, 2016, 34 (4):861-882.
[2]	Nentwich L M.Diagnosis of acute ischemic stoke[J].Emerg Med Clin North Am, 2016, 34 (4):837-859.
[3]	杨长春, 胡萍, 马增春.以纤溶酶原激活物抑制剂1为靶标的心血管疾病治疗研究进展[J].中华老年心脑血管病杂志, 2011, 13 (1):85-87.
[4]	d'Uscio L V, He T, Katusic Z S.Expression and processing of amyloid precursor protein in vascular endo-thelium[J].Physiology (Bethesda), 2017, 32 (1):20-32.
[5]	Luo J, Warmlander S K, Graslund A, et al.Cross-interactions between the Alzheimer Disease Amyloid-beta Peptide and Other Amyloid Proteins:A Further Aspect of the Amyloid Cascade Hypothesis[J].J Biol Chem, 2016, 29, 1 (32):16485-16493.
[6]	Haglund M, Kalaria R, Slade J Y, et al.Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia[J].Acta Neuropathol, 2006, 111 (5):430-435.
[7]	余猛飞, 常成, 张俊霞, 等.小鼠脊髓损伤后Aβ蛋白的表达与细胞凋亡[J].神经解剖学杂志, 2014, 30 (6):655-660.
[8]	中华医学会第四届全国脑血管病学术会议.各项脑血管诊断要点 (1995)[J].中华神经内科杂志, 1996, 29 (6):379-379.
[9]	Naess H, Kurtz M, Thomassen L, et al.Serial NIHSS scores in patients with acute cerebral infarction[J].Acta Neurol Scand, 2016, 133 (6):415-420.
[10]	刘小阳, 杜万红, 杨浩军, 等.丁苯肽对急性脑梗死患者血清TNF-α、CRP和神经功能缺损程度评分的影响[J].临床军医杂志, 2010, 38 (1):90-92.
[11]	杨仁华, 陈鹏.PAI-1与动脉粥样硬化[J].昆明医学院学报, 2012 (S1):198-201.
[12]	Ouyang L, Peng Y, Wu G, et al.Efffect of plasminogen activator inhibitor-1and endothelin-1on the atherosclerosis in the maintenance hemodialysis patients[J].Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2013, 38 (5):458-467.
[13]	Qian H S, Gu J M, Liu P, et al.Overexpression of PAI-1prevents the development of abdominal aortic aneurysm in mice[J].Gene Ther, 2008, 15 (3):224-232.
[14]	张凤梅, 王德宝, 吴鹤, 等.高尿酸血症患者血浆t-PA、PAI-1水平变化及与颈动脉粥样硬化的关系[J].山东医药, 2014, 54 (27):74-75.